Powerhouse Biology retweeted
Automation takes a task that formerly needed a human and makes it run on its own. This is extremely important and can increase throughput substantially. But reinventing the measurement can ALSO change throughput – to an even more substantial extent.
Powerhouse Biology retweeted
Today, the MitoCarta Tree of Life Consortium (MitoTOL) is releasing high-accuracy mitochondrial proteomes across diverse eukaryotes to empower studies of physiology, evolution, and disease:
cell.com/consortium/mitocart…
All data can be accessed at:
mitocarta.org
Powerhouse Biology retweeted
Scientists identified a self-perpetuating loop in Alzheimer's disease: tau damages mitochondria, mitochondria produce signals that make tau worse, tau damages mitochondria more. A Stanford-led study published in Neuron reveals the exact mechanism driving this cycle and how to break it.
Tau is a protein that's been heavily implicated in Alzheimer's disease and other neurodegenerative disorders. The standard view has been that tau forms tangled clumps called neurofibrillary tangles inside nerve cells, disrupting their structure. But mitochondrial dysfunction consistently appears alongside tau abnormalities across all tauopathies. The connection between these two hallmarks has remained unclear.
Mitochondria are your cells' energy factories. They generate ATP, the molecule that powers nearly every cellular process, by shuttling electrons through a series of protein complexes called the electron transport chain. Electrons normally flow forward through these complexes, from Complex I to Complex IV, producing energy efficiently.
Reverse electron transport, or RET, is when electrons flow backward through Complex I. Instead of generating useful energy, this reverse flow produces excess reactive oxygen species, or ROS. These are damaging molecules that oxidize proteins, lipids, and DNA. RET also depletes NAD+, a molecule critical for hundreds of metabolic reactions.
The new study demonstrates that tau directly regulates RET. When tau gets phosphorylated, meaning enzymes attach phosphate groups to specific sites on the protein, it enters mitochondria and binds to a Complex I subunit called NDUFS3. This interaction activates reverse electron transport.
Here's what the researchers found:
• Tau enters mitochondria and physically interacts with the NDUFS3 subunit of Complex I
• Phosphorylated tau enhances RET activation in a dose-dependent manner
• RET produces excess ROS and reduces the NAD+/NADH ratio
• The ROS and metabolic changes caused by RET drive further tau phosphorylation
• This creates a feed-forward loop where tau-induced RET makes tau more pathological
• Removing tau eliminates stress-induced RET entirely
The team tested this mechanism across three different model systems: fruit flies, mice, and human neurons derived from induced pluripotent stem cells. In all three systems, depleting tau prevented stress-induced RET and conferred significant protection against cellular stress.
When they blocked tau from entering mitochondria or disrupted the tau-NDUFS3 interaction, RET decreased. When they inhibited RET either genetically or pharmacologically, they protected against tau-induced neurodegeneration across all species tested.
The phosphorylation sites that enhanced RET activity corresponded to the same modifications found in human Alzheimer's disease brain tissue. This suggests the mechanism operates in actual disease conditions, not just experimental models.
What makes this discovery particularly important is that it reveals a normal function of tau that becomes pathological. Tau appears to regulate RET under physiological conditions, possibly as part of stress response signaling. During aging or chronic stress, this regulatory function spirals out of control.
The vicious cycle works like this: stress or aging triggers tau phosphorylation. Phosphorylated tau enters mitochondria and activates RET. RET produces oxidative stress and metabolic dysfunction. These changes drive more tau phosphorylation. More phosphorylated tau activates more RET. The loop reinforces itself.
This explains why mitochondrial dysfunction appears so consistently in tauopathies. It's not a separate problem running parallel to tau abnormalities. The two processes are mechanistically linked through RET, with each driving the other.
The therapeutic implications are direct. Blocking RET, preventing tau entry into mitochondria, or disrupting the tau-NDUFS3 interaction could all interrupt the pathological cycle. Several compounds that inhibit RET already exist, including metformin and rotenone at specific doses, though their therapeutic windows need careful definition.
The study also reframes how we think about neurofibrillary tangles. While tangles remain a pathological hallmark, the mitochondrial dysfunction driven by tau-RET interaction may cause neurodegeneration before tangles even form. Early intervention targeting this mechanism could prevent damage at stages where neurons remain salvageable.
Previous work showed that reducing tau levels protects against various neurological insults, from seizures to traumatic brain injury. This study provides a molecular explanation: without tau, cells can't activate pathological RET, maintaining mitochondrial function under stress.
The research identifies RET as a convergence point where tau's physiological function, its pathological modifications, and mitochondrial dysfunction all intersect. Understanding this intersection opens intervention strategies that target the mechanism driving neurodegeneration rather than just clearing protein aggregates after damage occurs.
Powerhouse Biology retweeted
Bender, Scannell, Shaywitz and colleagues in NRDD: a decade of AI in drug discovery, clinically relevant impact still limited. Their fix is right. Stop benchmarking model accuracy; benchmark whether the tool changes a real Go/No-Go. We proved translation is possible with Rentosertib. nature.com/articles/s41573-0…
Powerhouse Biology retweeted
Introducing PRIME, Cultivarium’s mitochondrial engineering program, supported by ARIA.
We’re developing tools for nucleic acid delivery, gene expression, and genome maintenance in mammalian mitochondria.
The non-model biology within us:
blog.cultivarium.org/p/the-n…
🤖 Made with AI
Powerhouse Biology retweeted
The article from Daphne is valuable; this plot is truly absurd.
- each "cell" from scRNAseq is 50K reads which is not 3GB, off by many magnitudes.
- we are a preseed company and work with 1PB of data- no causal map of biology is occurring LOL
- The amount of public sequencing data on NCBI well exceeds 100PB. still no causal map of biology.
- the idea that "more data" will solve biology is an absurd mental framework. it just makes AI+bio folks sound like a joke.
The data we need to understand human biology is about 1000x the quantity we've collected
Full piece from @insitro founder and CEO @DaphneKoller: a16z.news/p/drug-discovery-h…
Powerhouse Biology retweeted
What happens when you gather hundreds of builders and researchers at the frontiers of science and tech for three days of bouncing ideas, parties, and lab tours?
This weekend, we hosted our flagship event Vision Weekend! With a strong track record of matching scientists for collaborations, entrepreneurs with their first investors, and startups with early employees, we love seeing how these gatherings help turn big ideas into reality faster.
Thank you for building a better future with science and tech! Recordings of the talks will be available on our YouTube channel in a few weeks.
And a special thanks to our partners:
@AsteraInstitute @netholabs @protocollabs @ARIA_research @RetroBio_ and Poseidon Research
Powerhouse Biology retweeted
Towards genome editing for mitochondrial diseases
nature.com/articles/d41586-0…
Powerhouse Biology retweeted
Thanks to everyone who joined our AI x Bio workshop this weekend! 180 scientists, entrepreneurs, engineers, and funders gathered to explore how AI can accelerate longevity research.
The workshop included presentations on the current state of the field and its biggest bottlenecks, with insights from experts like @bettslacroix @DrMorganLevine @SGRodriques @jrkelly, as well as working groups to develop promising projects at the intersection between AI and biology.
Powerhouse Biology retweeted
Happy #NewMemberMonday!
👩🔬 @Powerhouse_Bio makes precision peptide therapeutics to combat mitochondrial dysfunction
💡 @serna_bio leverages AI to discover RNA-targeting small molecules
👨🔬 @TelixPharma drives radiopharmaceutical innovation from its base in Australia

ALT Happy #NewMemberMonday! 👩🔬 @Powerhouse_Bio makes precision peptide therapeutics to combat mitochondrial dysfunction 💡 @serna_bio leverages AI to discover RNA-targeting small molecules 👨🔬 @TelixPharma drives radiopharmaceutical innovation from its base in Australia 🧠 #CennaBiosciences develops novel treatments for Alzheimer's disease ✨ #NextureBio creates animal-component-free microcarriers, scaffolds, and cell-attachment factors 🔬 #StippleBio specializes in cellular profiling and target discovery using epitope resolution
Powerhouse Biology retweeted
NIH grants frozen. Discoveries delayed. PhDs pushed out. Academia getting gutted.
Innovation must continue. There’s never been a better time for scientists to build startups.
Powerhouse Biology retweeted
A human metabolic map of pharmacological perturbations reveals drug modes of action go.nature.com/3CreANg
Powerhouse Biology retweeted
Top altmetrics score 2024: #16🏆✨
@mitopinionated (@karolinskainst) and co-authors describe how inhibition of mitochondrial transcription reduces #OXPHOS capacity but increases fatty acid oxidation in the #liver, protecting against #obesity🧫🐭
nature.com/articles/s42255-0…
Powerhouse Biology retweeted
Over the years, people have asked: What does Asimov do? This is our brief response.
At a high level, we think biology is an advanced form of molecular nanotechnology. Our goal is to create tools and software to more reliably engineer cells, thus bolstering humanity’s ability to design living systems and enabling biotechnologies with outsized societal benefit.
Just because bioengineers can manipulate organisms, however, does not mean their well-laid plans come to fruition. Biological organisms are typically engineered, today, using iterative trial-and-error, rather than actual design. Our goal is to push biotechnology into a true engineering discipline, where experimental outcomes are predictable ahead of time.
Everything we do centers around a concept that we call genetic design. We think of this as the process of intentionally modifying an organism's DNA using advanced techniques such as characterized parts, modeling, and multi-omics analysis. Genetic design is distinct from traditional genetic engineering in that it focuses on forward design driven by biophysical understanding and model-guided predictions.
One of the ways we’re using genetic design is by engineering mammalian cells to make medicines. In other words, we’re making bio-tools, such as expression platforms and engineered cell lines, as well as software tools, including metabolic simulators, codon optimizers and signal peptide predictors, to help our customers engineer cells to make antibodies, AAV, and lentivirus.
A large part of our work is focused on antibodies, a type of protein used to make many of the most popular medicines, including Humira (for rheumatoid arthritis) and Keytruda (for cancer). Many pharmaceutical companies make antibodies using Chinese Hamster Ovary cells, or CHO, but the problem is that this process is unpredictable and has to be tweaked for every new antibody. We routinely use our wet-lab and software tools to optimize and engineer these cells, thus coaxing them to make greater amounts of antibodies with fast timelines and good quality attributes.
More recently, we also launched a product called LV Edge. LV stands for lentivirus, which is a type of virus that can be used to deliver genes into human cells for gene therapies. Lyfgenia, for example, was recently approved by the FDA and uses a lentiviral vector to add a hemoglobin gene to blood-making stem cells to treat sickle-cell disease. We engineered HEK293 (a type of immortalized human cell) to make large amounts of lentivirus, with the goal of making gene therapies available to more people. We’ve also written a longer blog about LV Edge, which you can read here. We have another product for AAV manufacturing, too, called AAV Edge.
Our basic “tech stack” is the same, regardless of whether we’re working on antibodies or anything else. We have teams actively working on optimizing cells and production processes for individual molecules and other teams building computational models — based on biophysical insights or transformer-based AI models — to predict aspects of how an engineered cell will behave before we make it. Another team within Asimov Labs collects large amounts of data in our Boston laboratory to measure the function of myriad biological processes, and then works with computational biology teams to improve their models. We strive to make every experiment into a data point so that nothing goes to waste.
Many of the models and tools we develop for various products are also bundled together and made available through Kernel, our browser-based software for genetic design. You can think of it as the “hub” or “vault” for all of the tools we’re building.
So that’s the gist. We make wet-lab and computational tools to engineer cells in more predictable ways. While engineering those cells, we collect a large amount of data and build models to understand how they work. This research, in turn, bolsters Kernel and makes it easier for everyone to design biology. In the future, we aim to expand our product offerings to agriculture, foods, and materials; anywhere that engineered biology can make an impact.
This and more at our website: asimov.com
Powerhouse Biology retweeted
Written by Liyam Chitayat
Read the essay and subscribe! press.asimov.com/articles/mi…
Powerhouse Biology retweeted
I’m thrilled to share that our paper “Machine-guided design of cell-type-targeting cis-regulatory elements” was published online in @Nature. nature.com/articles/s41586-0… #genomics #MachineLearning #SyntheticBiology #bioengineering 1/9
Powerhouse Biology retweeted
🎉 Congratulations to all the #iGEM2024 Grand Jamboree finalists! Your hard work and innovation to push the boundaries of biotechnology are truly inspiring. A special shout-out to Cultivarium-sponsored Overgraduate finalists, @igemmarburg and @igemaachen ! 🙌 #worldexposynbio
Powerhouse Biology retweeted
We’re humbled for our work to be featured in @NatureMedicine. Thanks for speaking with our CEO @ashleyz413 and we’re excited to keep everyone updated on our progress! More soon. #hiberation #biology #obesity
nature.com/articles/s41591-0…
Powerhouse Biology retweeted
I'd love to have a recurring salon like this for working on science communication content in general.
If I organized something in SF, who would be interested?
Announcing the Sci-Fi Salon.
Join @RichardMCNgo from OpenAI and @AlexandraBalwit from Asimov Press for an afternoon of science fiction writing.
We'll provide drinks & snacks.
August 17 / 4pm / San Francisco
Sign-up link in the next tweet.
































